Correction to: A phase I study of LY3164530, a bispecific antibody targeting MET and EGFR, in patients with advanced or metastatic cancer (Cancer Chemotherapy and Pharmacology, (2018), 82, 3, (407-418), 10.1007/s00280-018-3623-7)

Amita Patnaik, Michael Gordon, Frank Tsai, Kyriakos P. Papadopoulos, Drew Rasco, Muralidhar Beeram, Siqing Fu, Filip Janku, Scott M. Hynes, Sushma R. Gundala, Melinda D. Willard, Wei Zhang, Aimee Bence Lin, David Hong

Research output: Contribution to journalComment/debatepeer-review

Abstract

The original version of this article unfortunately contained a mistake. The co-authors’ names were incorrect.

Original languageEnglish (US)
Pages (from-to)419
Number of pages1
JournalCancer chemotherapy and pharmacology
Volume82
Issue number3
DOIs
StatePublished - Sep 1 2018

ASJC Scopus subject areas

  • Oncology
  • Toxicology
  • Pharmacology
  • Cancer Research
  • Pharmacology (medical)

Fingerprint

Dive into the research topics of 'Correction to: A phase I study of LY3164530, a bispecific antibody targeting MET and EGFR, in patients with advanced or metastatic cancer (Cancer Chemotherapy and Pharmacology, (2018), 82, 3, (407-418), 10.1007/s00280-018-3623-7)'. Together they form a unique fingerprint.

Cite this